• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Considerations in dosage selection for third generation cephalosporins.

作者信息

Yuk-Choi J H, Nightingale C H, Williams T W

机构信息

Department of Pharmacy Services, Methodist Hospital, Baylor College of Medicine, Houston, Texas.

出版信息

Clin Pharmacokinet. 1992 Feb;22(2):132-43. doi: 10.2165/00003088-199222020-00004.

DOI:10.2165/00003088-199222020-00004
PMID:1551290
Abstract

Pharmacokinetic parameters of third generation cephalosporins vary widely, requiring different dosage regimens and adjustment methods for each agent. Although their antibacterial spectrum favours their usage in infections caused by aerobic Gram-negative organisms, due to their limited post-antibiotic effect against these organisms, dosage regimens should ensure that free drug concentrations at the site of infection remain above the minimum inhibitory concentration for as much of the dosage interval as possible in patients with normal host defence mechanisms and for the entire dosage interval in immunocompromised patients. Altered protein binding encountered in various disease states can affect both microbiological and pharmacokinetic properties especially for drugs with high protein binding. Since the concentrations at the site of action are often different from those in serum, a higher or lower range of dosages needs to be selected depending on the target site. Decreased renal function affects the elimination of most third generation cephalosporins, whereas the presence of hepatic disease does not generally necessitate dosage adjustment. Because of the complex age-related physiological changes in paediatric and elderly patients, dosage should be adjusted on the basis of the reported pharmacokinetic data in these populations. The usual recommended dose may or may not be optimal in a given condition depending on the complex interactions between pharmacokinetic, microbiological and other host factors.

摘要

相似文献

1
Considerations in dosage selection for third generation cephalosporins.
Clin Pharmacokinet. 1992 Feb;22(2):132-43. doi: 10.2165/00003088-199222020-00004.
2
[Review of oral cephalosporins. Basis for a rational choice].[口服头孢菌素综述。合理选择的依据]
Medicina (B Aires). 1994;54(5 Pt 1):439-58.
3
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.头孢洛扎/他唑巴坦:一种新型头孢菌素/β-内酰胺酶抑制剂组合
Pharmacotherapy. 2015 Jul;35(7):701-15. doi: 10.1002/phar.1609. Epub 2015 Jul 1.
4
A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.头孢洛林酯在特定人群中的一系列药代动力学研究:正常受试者、健康老年受试者以及有肾功能损害或需要血液透析的终末期肾病受试者。
J Clin Pharmacol. 2014 Jul;54(7):742-52. doi: 10.1002/jcph.265. Epub 2014 Jan 22.
5
[Cefoperazone and other third-generation cephalosporins].头孢哌酮及其他第三代头孢菌素
Antibiot Khimioter. 1992 Oct;37(10):52-4.
6
[Antibiotic activities of cefpirome against fresh clinical isolates resistant to multiple drugs].头孢匹罗对多重耐药新鲜临床分离株的抗菌活性
Jpn J Antibiot. 1994 Feb;47(2):143-60.
7
In vitro and in vivo antibacterial activities of ME1220 and ME1221, novel cephalosporins.新型头孢菌素ME1220和ME1221的体外和体内抗菌活性
Drugs Exp Clin Res. 1991;17(4):205-12.
8
The pharmacokinetics of cefpirome--rationale for a twelve-hour dosing regimen.头孢匹罗的药代动力学——12小时给药方案的理论依据。
Scand J Infect Dis Suppl. 1993;91:33-40.
9
Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.头孢呋辛酯:一种新型的广谱头孢菌素,具有扩展的抗革兰氏阳性活性。
J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv9-16. doi: 10.1093/jac/dkq251.
10
Clinical pharmacokinetics of the third generation cephalosporins.第三代头孢菌素的临床药代动力学
Clin Pharmacokinet. 1985 Mar-Apr;10(2):101-43. doi: 10.2165/00003088-198510020-00001.

引用本文的文献

1
Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.住院儿科患者常用的抗菌和抗真菌药物:基于临床药代动力学对治疗的影响
Paediatr Drugs. 2001;3(10):733-61. doi: 10.2165/00128072-200103100-00003.
2
Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.胃肠外头孢菌素类药物的药理学特性:门诊使用的理论依据。
Drugs. 2000;59 Suppl 3:9-18; discussion 47-9. doi: 10.2165/00003495-200059003-00002.
3
Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

本文引用的文献

1
Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels.给药方案对青霉素治疗效果的影响;青霉素维持有效杀菌水平的累计时间的重要性。
Am J Med. 1950 Sep;9(3):280-99. doi: 10.1016/0002-9343(50)90425-6.
2
Penetration of ceforanide and cefamandole into the right atrial appendage, pericardial fluid, sternum, and intercostal muscle of patients undergoing open heart surgery.头孢乙腈和头孢孟多在接受心脏直视手术患者的右心耳、心包液、胸骨和肋间肌中的渗透情况。
Antimicrob Agents Chemother. 1982 Mar;21(3):416-20. doi: 10.1128/AAC.21.3.416.
3
头孢曲松。对其用于治疗严重感染的药物经济学评价。
Pharmacoeconomics. 1994 Sep;6(3):249-69. doi: 10.2165/00019053-199406030-00009.
4
Pharmacokinetics of drugs used in critically ill adults.危重症成年患者使用药物的药代动力学
Clin Pharmacokinet. 1998 Jan;34(1):25-56. doi: 10.2165/00003088-199834010-00002.
5
Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.第三代头孢菌素的药物利用评价。重点关注头孢曲松、头孢他啶和头孢噻肟。
Drugs. 1995 Sep;50(3):423-39. doi: 10.2165/00003495-199550030-00002.
6
Clinical pharmacokinetics of cefotetan.头孢替坦的临床药代动力学
Clin Pharmacokinet. 1994 Apr;26(4):248-58. doi: 10.2165/00003088-199426040-00002.
7
Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.头孢他美酯。其抗菌活性、药代动力学特性及治疗用途综述。
Drugs. 1993 Apr;45(4):589-621. doi: 10.2165/00003495-199345040-00009.
Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.
浓度依赖性血浆蛋白结合对头孢曲松动力学的影响。
Clin Pharmacol Ther. 1981 May;29(5):650-7. doi: 10.1038/clpt.1981.90.
4
Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes.抗生素后白细胞增强:用抗生素预处理的细菌对白细胞活性的敏感性增加。
Rev Infect Dis. 1981 Jan-Feb;3(1):38-44. doi: 10.1093/clinids/3.1.38.
5
Bacterial kill rates of amoxycillin and ampicillin at exponentially diminishing concentrations simulating in vivo conditions.在模拟体内条件下,阿莫西林和氨苄西林在指数递减浓度时的细菌杀灭率。
Infection. 1980;Suppl 1:103-8. doi: 10.1007/BF01644943.
6
Penetration characteristics of cefamandole into the right atrial appendage and pericardial fluid in patients undergoing open-heart surgery.
Ann Thorac Surg. 1980 Feb;29(2):104-8. doi: 10.1016/s0003-4975(10)61644-x.
7
Postantibiotic suppression of bacterial growth.抗生素后细菌生长抑制
Rev Infect Dis. 1981 Jan-Feb;3(1):28-37. doi: 10.1093/clinids/3.1.28.
8
Pharmacokinetics of cefpiramide (SM-1652) in humans.头孢匹胺(SM-1652)在人体内的药代动力学。
Antimicrob Agents Chemother. 1984 Feb;25(2):221-5. doi: 10.1128/AAC.25.2.221.
9
Pharmacokinetics of moxalactam in elderly subjects.老年人中莫西拉坦的药代动力学
Antimicrob Agents Chemother. 1984 Jan;25(1):33-6. doi: 10.1128/AAC.25.1.33.
10
Tissue penetration and half-life of cefonicid.头孢尼西的组织穿透性和半衰期。
Rev Infect Dis. 1984 Nov-Dec;6 Suppl 4:S821-8. doi: 10.1093/clinids/6.supplement_4.s821.